Research Analysts Set Expectations for BHC FY2025 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Stock analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for shares of Bausch Health Companies in a report issued on Monday, January 20th. Zacks Research analyst R. Department now forecasts that the company will earn $4.23 per share for the year, down from their prior forecast of $4.28. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.73 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2026 earnings at $1.27 EPS and FY2026 earnings at $4.90 EPS.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.10. The firm had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The business’s revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.03 EPS.

BHC has been the topic of a number of other research reports. Royal Bank of Canada upped their price target on shares of Bausch Health Companies from $10.00 to $11.00 and gave the company a “sector perform” rating in a research report on Friday, November 1st. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Finally, Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Bausch Health Companies has an average rating of “Hold” and a consensus target price of $7.75.

Bausch Health Companies Stock Up 3.4 %

NYSE:BHC opened at $7.73 on Thursday. Bausch Health Companies has a 52 week low of $3.96 and a 52 week high of $11.46. The firm’s fifty day moving average is $7.86 and its 200-day moving average is $7.45.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BHC. DGS Capital Management LLC bought a new stake in shares of Bausch Health Companies during the fourth quarter worth about $143,000. Merit Financial Group LLC acquired a new position in Bausch Health Companies during the 4th quarter valued at about $228,000. Sanders Morris Harris LLC increased its holdings in Bausch Health Companies by 16.0% during the 4th quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock worth $234,000 after purchasing an additional 4,000 shares in the last quarter. Northwest & Ethical Investments L.P. raised its stake in shares of Bausch Health Companies by 13.0% in the third quarter. Northwest & Ethical Investments L.P. now owns 32,384 shares of the company’s stock worth $264,000 after purchasing an additional 3,734 shares during the last quarter. Finally, Creative Planning lifted its holdings in shares of Bausch Health Companies by 16.9% in the third quarter. Creative Planning now owns 55,351 shares of the company’s stock valued at $452,000 after purchasing an additional 7,995 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.